Hepion Pharmaceuticals Inc. Watch

from 8-K 3 pages Termination Agreement

from 425 5 pages Lock-Up Agreement [●], 2024

from 8-K 5 pages Lock-Up Agreement [●], 2024

from 8-K 6 pages Form of Support Agreement

from 425 6 pages Form of Support Agreement

from 425 23 pages Registration Rights Agreement

from 8-K 23 pages Registration Rights Agreement

from 8-K 26 pages Securities Purchase Agreement

from 425 26 pages Securities Purchase Agreement

from 8-K 2 pages Amendment No. 1 to Series a Common Stock Purchase Warrant

from 8-K 13 pages February 15, 2024 to the Holder of Series B Common Stock Purchase Warrants of Hepion Pharmaceuticals, Inc. Issued on October 3, 2023 Re: Warrant Inducement Agreement Dear Holder

from 8-K 44 pages Securities Purchase Agreement

from 8-K 21 pages This Letter Agreement (This “Letter Agreement”) Is Being Entered Into in Connection With, and as a Condition To, the Parties’ Execution and Delivery of the Securities Purchase Agreement, Pursuant to Which the Purchaser Agreed to Purchase From the Company, and the Company Agreed to Sell and Issue to the Purchaser, Upon the Terms and Subject to the Conditions Stated in the Securities Purchase Agreement, Shares of the Company’s Preferred Stock. Capitalized Terms Used Herein but Not Otherwise Defined Shall Have the Meaning Given to Such Terms in the Securities Purchase Agreement. to Induce the Parties to Enter Into the Securities Purchase Agreement, the Purchaser and the Company Hereby Agree as Follows: 1. Voting of Preferred Stock

from 8-K 27 pages Registration Rights Agreement

from 8-K 41 pages Securities Purchase Agreement

from S-1/A 3 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amendment No. 1 to Nicams Purchase and Sale Agreement May 26, 2016

from S-1/A 46 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from S-1/A 21 pages Common Stock Purchase Warrant Contravir Pharmaceuticals, Inc

from S-1 44 pages Agreement and Plan of Merger by and Among Contravir Pharmaceuticals, Inc., Ciclofilin Acquisition Corp., Ciclofilin Pharmaceuticals, Inc. and Robert Foster, PHARM.D., PH.D., as Stockholder Representative Dated as of May 26, 2016 Agreement of Plan and Merger

from S-1/A 34 pages Securities Purchase Agreement